Cargando…
Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori
Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology. This phenomenon is greatly associated with a very narr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599531/ https://www.ncbi.nlm.nih.gov/pubmed/33007899 http://dx.doi.org/10.3390/antibiotics9100658 |
_version_ | 1783602897734336512 |
---|---|
author | Krzyżek, Paweł Paluch, Emil Gościniak, Grażyna |
author_facet | Krzyżek, Paweł Paluch, Emil Gościniak, Grażyna |
author_sort | Krzyżek, Paweł |
collection | PubMed |
description | Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology. This phenomenon is greatly associated with a very narrow range of antibiotics used in standard therapies and, as a consequence, an alarmingly high detection of multidrug-resistant H. pylori strains. For this reason, scientists are increasingly focused on the search for new substances that will not only exhibit antibacterial effect against H. pylori, but also potentiate the activity of antibiotics. The aim of the current review is to present scientific reports showing newly discovered or repurposed compounds with an ability to enhance the antimicrobial activity of classically used antibiotics against H. pylori. To gain a broader context in their future application in therapies of H. pylori infections, their antimicrobial properties, such as minimal inhibitory concentrations and minimal bactericidal concentrations, dose- and time-dependent mode of action, and, if characterized, anti-biofilm and/or in vivo activity are further described. The authors of this review hope that this article will encourage the scientific community to expand research on the important issue of synergistic therapies in the context of combating H. pylori infections. |
format | Online Article Text |
id | pubmed-7599531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75995312020-11-01 Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori Krzyżek, Paweł Paluch, Emil Gościniak, Grażyna Antibiotics (Basel) Review Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology. This phenomenon is greatly associated with a very narrow range of antibiotics used in standard therapies and, as a consequence, an alarmingly high detection of multidrug-resistant H. pylori strains. For this reason, scientists are increasingly focused on the search for new substances that will not only exhibit antibacterial effect against H. pylori, but also potentiate the activity of antibiotics. The aim of the current review is to present scientific reports showing newly discovered or repurposed compounds with an ability to enhance the antimicrobial activity of classically used antibiotics against H. pylori. To gain a broader context in their future application in therapies of H. pylori infections, their antimicrobial properties, such as minimal inhibitory concentrations and minimal bactericidal concentrations, dose- and time-dependent mode of action, and, if characterized, anti-biofilm and/or in vivo activity are further described. The authors of this review hope that this article will encourage the scientific community to expand research on the important issue of synergistic therapies in the context of combating H. pylori infections. MDPI 2020-09-30 /pmc/articles/PMC7599531/ /pubmed/33007899 http://dx.doi.org/10.3390/antibiotics9100658 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Krzyżek, Paweł Paluch, Emil Gościniak, Grażyna Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori |
title | Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori |
title_full | Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori |
title_fullStr | Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori |
title_full_unstemmed | Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori |
title_short | Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori |
title_sort | synergistic therapies as a promising option for the treatment of antibiotic-resistant helicobacter pylori |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599531/ https://www.ncbi.nlm.nih.gov/pubmed/33007899 http://dx.doi.org/10.3390/antibiotics9100658 |
work_keys_str_mv | AT krzyzekpaweł synergistictherapiesasapromisingoptionforthetreatmentofantibioticresistanthelicobacterpylori AT paluchemil synergistictherapiesasapromisingoptionforthetreatmentofantibioticresistanthelicobacterpylori AT gosciniakgrazyna synergistictherapiesasapromisingoptionforthetreatmentofantibioticresistanthelicobacterpylori |